Abstract:Using proteomics analysis, we previously compared MCF7 breast cancer cells grown as 3D tumor spheres, with the same cell line grown as monolayers. Our results indicated that during 3D anchorage-independent growth, the cellular machinery associated with i) mitochondrial biogenesis and ii) ribosomal biogenesis, were both significantly increased. Here, for simplicity, we refer to these two new oncogenic hallmarks as "mito-stemness" and "ribo-stemness" features. We have now applied this same type of strategy to begin to understand how fibroblasts and MCF7 breast cancer cells change their molecular phenotype, when they are co-cultured together. We have previously shown that MCF7-fibroblast co-cultures are a valuable model of resistance to apoptosis induced by hormonal therapies, such as Tamoxifen and Fulvestrant. Here, we directly show that these mixed co-cultures demonstrate the induction of mito-stemness and ribo-stemness features, likely reflecting a mechanism for cancer cells to increase their capacity for accumulating biomass. In accordance with the onset of a stem-like phenotype, KRT19 (keratin 19) was induced by ~6-fold during co-culture. KRT19 is a well-established epithelial CSC marker that is used clinically to identify metastatic breast cancer cells in sentinel lymph node biopsies. The potential molecular therapeutic targets that we identified by label-free proteomics of MCF7-fibroblast co-cultures were then independently validated using a bioinformatics approach. More specifically, we employed publically-available transcriptional profiling data derived from primary tumor samples from breast cancer patients, which were previously subjected to laser-capture micro-dissection, to physically separate breast cancer cells from adjacent tumor stroma. This allowed us to directly validate that the proteins up-regulated in this co-culture model were also transcriptionally elevated in patient-derived breast cancer cells in vivo. This powerful approach for target identification and translational validation, including the use of patient outcome data, can now be applied to other tumor types as well, to validate new therapeutic targets that are more clinically relevant, for patient benefit. Moreover, we discuss the therapeutic implications of these findings for new drug development, drug repurposing and Tamoxifen-resistance, to effectively target mito-stemness and ribo-stemness features in breast cancer patients. We also discuss the broad implications of this "organelle biogenesis" approach to cancer therapy.

Ribosome biogenesis and ribosomal proteins in cancer stem cells: a new therapeutic prospect

Ribosome biogenesis in cancer: new players and therapeutic avenues

Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer

Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy

Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?

Abstract 2768: Ribosome biogenesis score: Prognostic insights and drug responses in cancer

Dysregulation of mitophagy and mitochondrial homeostasis in cancer stem cells: Novel mechanism for anti‐cancer stem cell‐targeted cancer therapy

Ribosome biogenesis in disease: new players and therapeutic targets

Ribosomal Proteins and Cancer

Biomolecular characterization of exosomes released from cancer stem cells: Possible implications for biomarker and treatment of cancer

Potentials of Ribosomopathy Gene As Pharmaceutical Targets for Cancer Treatment

Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer: Mito-stemness and ribo-stemness features

Decoding ribosome complexity: role of ribosomal proteins in cancer and disease

Decoding the ribosome's hidden language: rRNA modifications as key players in cancer dynamics and targeted therapies

Targeting Ribosome Biogenesis as a Novel Therapeutic Approach to Overcome EMT-related Chemoresistance in Breast Cancer.

Stem Cell-Derived Exosomes: An Advanced Horizon to Cancer Regenerative Medicine

Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance

Nanoparticle-Based RNAi Therapeutics Targeting Cancer Stem Cells: Update and Prospective

microRNAs in cancer stem cells: Biology, pathways, and therapeutic opportunities

Intricate relationship between cancer stemness, metastasis, and drug resistance

Novel Anti-Cancer Stem Cell Compounds: A Comprehensive Review